Teva's Exclusivity For Cozaar And Hyzaar Generics Imperiled Once Again
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA tells court it is considering whether the fact that the patent has expired because Merck did not pay maintenance fees means that Teva could lose its 180-day prize.